Whether she engaged the (a) Agricultural Research Council (ARC) and (b) Onderstepoort Biological Products (OBP) as well as Industry, including the National Animal Health Forum, and instructed that measures be put in place to ensure continuity in vaccine production and
availability; if not, why not, in each case; if so, what are the relevant details in each case;
(2) whether she advised that there should be closer collaboration between the ARC’s Onderstepoort Veterinary Research and OBP; if not, what is the position in this regard; if so, what are the relevant details of the outcomes of those engagements, including the total amount of vaccines produced after the engagement compared to past production? NW1870E